Feasibility Studies of Personalized Closed Loop

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-20

Study Completion Date

2022-01-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single arm study comprised of a series of feasibility studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

NCT04877730

Type 1 Diabetes

COMPLETED NA

International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol

NCT02844517

Diabetes Mellitus, Type 1

COMPLETED NA

The International Diabetes Closed Loop (iDCL) Trial: Protocol 1

NCT02985866

Type1 Diabetes Mellitus

COMPLETED NA

A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery

NCT01492062

Type 1 Diabetes Mellitus

WITHDRAWN NA

Overnight Closed Loop Study in U.S.

NCT01857973

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Feasibility Study Part 2 (i.e. Feasibility 2): Feasibility 2 is the focus of the current version of the study protocol.

This study will include 2 separate Cohorts of individuals, based on the algorithms being studied:

Cohort A: The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm adaptation

Cohort C: The main purpose of this cohort is to test a meal prediction algorithm

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single Arm (Cohort) assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Algorithm Testing

The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm

The study population will be enrolled as 2 separate cohorts to test each algorithms individually

Group Type EXPERIMENTAL

Cloud-based Digital Twin and Meal Prediction algorithms

Intervention Type DEVICE

Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cloud-based Digital Twin and Meal Prediction algorithms

Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is age 2-80 years at time of Visit 1. Note: See staged enrollment reference for adult and pediatric subjects in the Study Design section
2. Subject has a clinical diagnosis of type 1 diabetes.

1. Subjects 7 years of age and older: Diagnosed at least 1 year prior to Visit 1
2. Subjects 2-6 years of age: Diagnosed at least 3 months prior to Visit 1

3. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units.
4. If subject has a history of hypothyroidism, must have at least 1 documented normal thyroid-stimulating hormone (TSH) on historical labs within 12 months of Visit 1. A subject without a history of hyperthyroidism is not expected to have a TSH test
5. Subjects and their parent(s)/guardian(s) must have Internet access , a computer system that meets the requirements for uploading the study pump and Smartphone that meets study requirements.
6. Subject must have a companion or caregiver available at night for the duration of the study period who resides (or will live) in in the same building (or home). This requirement may be verified by subject report at screening visit.
7. If subject has celiac disease, it has been adequately treated as determined by the investigator.
8. Subjects and their parent(s)/guardian(s) are willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)

* Humalog™\* (insulin lispro injection)
* NovoLog™\* (insulin aspart)

Exclusion Criteria

1. Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in any the following during the last 1 year prior to Visit 1

1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)
2. Coma
3. Seizures
2. Subject is unable to tolerate tape adhesive in the area of sensor placement.
3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
4. Women of child-bearing potential who have a positive pregnancy test at Visit 1 or plan to become pregnant during the course of the study
5. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
6. Subject has a cardiovascular condition which the Study Investigator determines should exclude the subject, e.g. ventricular rhythm disturbance, hypertrophic cardiomyopathy, recent myocardial infarction in the last year prior to Visit 1.
7. Subject is being treated for hyperthyroidism at time of Visit 1.
8. Subject has a diagnosis of adrenal insufficiency.
9. Subject has had Diabetic Ketoacidosis (DKA) within 1 year prior to Visit 1.
10. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of visit 1, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.
11. Subject is actively participating in an investigational study (e.g., drug or device) wherein he/she has received treatment from an investigational study (drug or device) in the last 2 weeks prior to Visit 1. Please note participation in observational study is acceptable.
12. Subject has been hospitalized or has visited the ER in the 6 months prior to Visit 1 resulting in a primary diagnosis of uncontrolled diabetes.
13. Subject is currently abusing illicit drugs.
14. Subject is currently abusing alcohol.
15. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of Visit 1.
16. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator.
17. Subject has elective surgery planned that requires general anesthesia during the course of the study.
18. Subject diagnosed with current eating disorder such as anorexia or bulimia.
19. Subject has been diagnosed with chronic kidney disease that results in chronic anemia.
20. Subject is on dialysis.
21. Subject has serum creatinine of \>2 mg/dL, as confirmed through historical labs within 1 year prior to Visit 1.
22. Subject is a member the research staff involved with the study.

Minimum Eligible Age

2 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No